Suppr超能文献

包裹肿瘤簇的血管(VETC)模式可预测辅助性 TACE 在肝细胞癌中的疗效。

Vessels that encapsulate tumor clusters (VETC) pattern predicts the efficacy of adjuvant TACE in hepatocellular carcinoma.

机构信息

Department of Abdominal Surgery, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, 78 Hengzhigang Road, Guangzhou, 510095, Guangdong, China.

Department of Medical Oncology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, 510095, Guangdong, China.

出版信息

J Cancer Res Clin Oncol. 2023 Jul;149(8):4163-4172. doi: 10.1007/s00432-022-04323-4. Epub 2022 Sep 1.

Abstract

PURPOSE

Postoperative adjuvant trans-catheter arterial chemoembolization (TACE) is regarded as a common strategy for hepatocellular carcinoma (HCC) patients at a high risk of recurrence. However, there are currently no clinically available biomarkers to predict adjuvant TACE response. Vessels that encapsulate tumor clusters (VETC) can be used as an independent predictor of HCC prognosis. In this study, we aimed to explore whether the VETC pattern could predict adjuvant TACE benefit.

METHODS

Vascular pattern and HIF-1α expression were detected in immunohistochemistry. The survival benefit of adjuvant TACE therapy for patients with or without VETC pattern (VETC+ /VETC-) was evaluated.

RESULTS

The adjuvant TACE therapy obviously improved the TTR and OS in VETC+ patients, while adjuvant TACE therapy could not benefit from VETC- patients. Univariate and multivariate analysis revealed that adjuvant TACE therapy significantly improved the TTR and OS in VETC+ patients, but not in VETC- patients. In addition, the VETC+ , but not VETC- , patients could benefit from adjuvant TACE therapy in patients with high-risk factors of vascular invasion, larger tumor or multiple tumor. The mechanistic investigations revealed that the favorable efficacy of adjuvant TACE on VETC+ patients, but not VETC- ones, may be not due to the activation of HIF-1α pathway.

CONCLUSION

The VETC pattern may represent a novel and reliable factor for selecting HCC patients who may benefit from adjuvant TACE therapy, and the combination of VETC pattern and tumor characteristics may help stratify patients' outcomes and responses to adjuvant TACE therapy.

摘要

目的

术后经导管动脉化疗栓塞(TACE)被认为是肝癌(HCC)高复发风险患者的常用策略。然而,目前尚无临床可用的生物标志物来预测辅助 TACE 反应。包裹肿瘤簇的血管(VETC)可作为 HCC 预后的独立预测因子。在本研究中,我们旨在探讨 VETC 模式是否可预测辅助 TACE 获益。

方法

采用免疫组织化学检测血管模式和 HIF-1α 表达。评估有无 VETC 模式(VETC+ / VETC-)的患者接受辅助 TACE 治疗的生存获益。

结果

辅助 TACE 治疗明显改善了 VETC+患者的 TTR 和 OS,而辅助 TACE 治疗对 VETC-患者则无获益。单因素和多因素分析显示,辅助 TACE 治疗显著改善了 VETC+患者的 TTR 和 OS,但对 VETC-患者则无此作用。此外,VETC+患者(而非 VETC-患者)在具有血管侵犯、较大肿瘤或多个肿瘤等高危因素的患者中可从辅助 TACE 治疗中获益。机制研究表明,辅助 TACE 对 VETC+患者的良好疗效(而非 VETC-患者)可能并非由于 HIF-1α 通路的激活所致。

结论

VETC 模式可能是选择可能从辅助 TACE 治疗中获益的 HCC 患者的一个新的可靠因素,VETC 模式与肿瘤特征的结合可能有助于分层患者的结局和对辅助 TACE 治疗的反应。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验